Skip Navigation


Mol. Hum. Reprod. Advance Access originally published online on September 18, 2008
Molecular Human Reproduction 2008 14(10):603-611; doi:10.1093/molehr/gan051
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
14/10/603    most recent
gan051v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Heng, K.
Right arrow Articles by Anand-Ivell, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heng, K.
Right arrow Articles by Anand-Ivell, R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Relaxin signalling in primary cultures of human myometrial cells

Kee Heng1, Richard Ivell1, Prabhath Wagaarachchi2 and Ravinder Anand-Ivell1,3

1School of Molecular and Biomedical Science, University of Adelaide, Adelaide SA5005, Australia 2Department of Perinatal Medicine, Women's and Children's Hospital, North Adelaide SA 5006, Australia

3 Correspondence address. E-mail: ravinder.anand-ivell{at}adelaide.edu.au

In myometrium of pigs and rats, though not humans, relaxin appears to mediate an inhibition of spontaneous and oxytocin-induced contractility, presumably acting through a G-protein coupled receptor (RXFP1) to generate cAMP. In humans, circulating relaxin is highest in the first trimester, including the time of implantation, when transitory uterine quiescence could help a blastocyst to implant. We investigated whether relaxin can activate adenylate cyclase in primary human myometrial cells from non-pregnant tissue, and we show that relaxin is able to stimulate the generation of cAMP in a manner, which is dependent upon a tyrosine phosphorylation activity, as in the endometrium. We identified transcripts for the relaxin receptor RXFP1 as full-length variants, though a minor splice variant missing exon 2 was also present in low amounts. These cells also express transcripts encoding RXFP2, the receptor for the closely related hormone, INSL3. Although able to respond to relaxin at high concentrations, this receptor does not appear to function by contributing to the cAMP production in human myometrial cells, nor does INSL3 act as a functional agonist or antagonist of relaxin action. In conclusion, the inability of relaxin to inhibit contractility in human myometrial cells would appear to be due to events downstream of simple cAMP generation.

Key words: relaxin/human myometrium/INSL3/uterine quiescence/menstrual cycle

Submitted on April 14, 2008; resubmitted on September 5, 2008; accepted on September 8, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Biol. Reprod.Home page
R. Anand-Ivell, K. Heng, B. Hafen, B. Setchell, and R. Ivell
Dynamics of INSL3 Peptide Expression in the Rodent Testis
Biol Reprod, September 1, 2009; 81(3): 480 - 487.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
R. Ivell and R. Anand-Ivell
Biology of insulin-like factor 3 in human reproduction
Hum. Reprod. Update, July 1, 2009; 15(4): 463 - 476.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.